Literature DB >> 8138058

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans.

C Orskov1, L Rabenhøj, A Wettergren, H Kofod, J J Holst.   

Abstract

Using specific radioimmunoassays, we studied the occurrence of amidated and glycine-extended glucagon-like peptide I (GLP-I) molecules in the human small intestine and pancreas and in the circulation system in response to a breakfast meal. Through gel permeation chromatography of extracts of the human pancreas (n = 5), we found that 71% of the GLP-I immunoreactivity eluted as a large molecule corresponding to the major proglucagon fragment, 24% corresponded to GLP-I 1-36 amide, and 5% to GLP-I 1-37. By gel permeation chromatography of extracts of human small intestine (n = 6), we found that all immunoreactivity eluted in one peak at the common elution position of the two insulin-releasing peptides, GLP-I 7-36 amide and GLP-I 7-37. Of the GLP-I immunoreactivity, 80% corresponded to GLP-I 7-36 amide and 20% to GLP-I 7-37. The mean concentrations of amidated GLP-I and glycine-extended GLP-I in fasting plasma were 7 +/- 1 and 6 +/- 1 pM, respectively (n = 6). In response to a breakfast meal, the concentration of amidated GLP-I rose significantly amounting to 41 +/- 5 pM 90 min after the meal ingestion, whereas the concentration of glycine-extended GLP-I only rose slightly to a maximum of 10 +/- 1 pM. Thus, both amidated and glycine-extended GLP-I molecules are produced in the small intestine and in the pancreas in humans. Both amidated and glycine-extended GLP-I are measurable in fasting plasma.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8138058     DOI: 10.2337/diab.43.4.535

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  220 in total

Review 1.  Bowels control brain: gut hormones and obesity.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Nat Rev Endocrinol       Date:  2010-06-29       Impact factor: 43.330

2.  Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent "compound 2" at the GLP-1 receptor.

Authors:  Karen Coopman; Yan Huang; Neil Johnston; Sophie J Bradley; Graeme F Wilkinson; Gary B Willars
Journal:  J Pharmacol Exp Ther       Date:  2010-05-27       Impact factor: 4.030

Review 3.  Regulation of energy balance by a gut-brain axis and involvement of the gut microbiota.

Authors:  Paige V Bauer; Sophie C Hamr; Frank A Duca
Journal:  Cell Mol Life Sci       Date:  2015-11-05       Impact factor: 9.261

4.  Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.

Authors:  M S Svane; N B Jørgensen; K N Bojsen-Møller; C Dirksen; S Nielsen; V B Kristiansen; S Toräng; N J Wewer Albrechtsen; J F Rehfeld; B Hartmann; S Madsbad; J J Holst
Journal:  Int J Obes (Lond)       Date:  2016-08-30       Impact factor: 5.095

Review 5.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

6.  Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes.

Authors:  D H Jensen; K Aaboe; J E Henriksen; A Vølund; J J Holst; S Madsbad; T Krarup
Journal:  Diabetologia       Date:  2012-05       Impact factor: 10.122

7.  Effects of Diet on Bile Acid Metabolism and Insulin Resistance in Type 2 Diabetic Rats after Roux-en-Y Gastric Bypass.

Authors:  Cheng-Xiang Shan; Nian-Cun Qiu; Miao-E Liu; Si-Luo Zha; Xin Song; Zhi-Peng Du; Wen-Sheng Rao; Dao-Zhen Jiang; Wei Zhang; Ming Qiu
Journal:  Obes Surg       Date:  2018-10       Impact factor: 4.129

8.  Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin.

Authors:  T Tolessa; M Gutniak; J J Holst; S Efendic; P M Hellström
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

9.  Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass.

Authors:  Carsten Dirksen; Kirstine N Bojsen-Møller; Nils B Jørgensen; Siv H Jacobsen; Viggo B Kristiansen; Lars S Naver; Dorte L Hansen; Dorte Worm; Jens J Holst; Sten Madsbad
Journal:  Diabetologia       Date:  2013-09-19       Impact factor: 10.122

10.  In vivo biological activity of exendin (1-30).

Authors:  Máire E Doyle; Patrick McConville; Michael J Theodorakis; Margaret M Goetschkes; Michel Bernier; Richard G S Spencer; Harold W Holloway; Nigel H Greig; Josephine M Egan
Journal:  Endocrine       Date:  2005-06       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.